120 related articles for article (PubMed ID: 19664735)
1. Direct healthcare costs of hip, vertebral, and non-hip, non-vertebral fractures.
Shi N; Foley K; Lenhart G; Badamgarav E
Bone; 2009 Dec; 45(6):1084-90. PubMed ID: 19664735
[TBL] [Abstract][Full Text] [Related]
2. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
3. PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis.
Danese MD; Kim J; Doan QV; Dylan M; Griffiths R; Chertow GM
Am J Kidney Dis; 2006 Jan; 47(1):149-56. PubMed ID: 16377396
[TBL] [Abstract][Full Text] [Related]
4. Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden.
Ström O; Borgstrom F; Zethraeus N; Johnell O; Lidgren L; Ponzer S; Svensson O; Abdon P; Ornstein E; Ceder L; Thorngren KG; Sernbo I; Jonsson B
Acta Orthop; 2008 Apr; 79(2):269-80. PubMed ID: 18484255
[TBL] [Abstract][Full Text] [Related]
5. Supplemental calcium for the prevention of hip fracture: potential health-economic benefits.
Bendich A; Leader S; Muhuri P
Clin Ther; 1999 Jun; 21(6):1058-72. PubMed ID: 10440627
[TBL] [Abstract][Full Text] [Related]
6. Incidence and costs of osteoporosis-associated hip fractures in Austria.
Koeck CM; Schwappach DL; Niemann FM; Strassmann TJ; Ebner H; Klaushofer K
Wien Klin Wochenschr; 2001 May; 113(10):371-7. PubMed ID: 11432126
[TBL] [Abstract][Full Text] [Related]
7. Cost analysis of osteoporotic hip fractures.
Woratanarat P; Wajanavisit W; Lertbusayanukul C; Loahacharoensombat W; Ongphiphatanakul B
J Med Assoc Thai; 2005 Oct; 88 Suppl 5():S96-104. PubMed ID: 16869109
[TBL] [Abstract][Full Text] [Related]
8. The societal burden of osteoporosis in Sweden.
Borgström F; Sobocki P; Ström O; Jönsson B
Bone; 2007 Jun; 40(6):1602-9. PubMed ID: 17433804
[TBL] [Abstract][Full Text] [Related]
9. Hospital care of osteoporosis-related vertebral fractures.
Gehlbach SH; Burge RT; Puleo E; Klar J
Osteoporos Int; 2003 Jan; 14(1):53-60. PubMed ID: 12577185
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of vitamin D inadequacy in Scottish adults with non-vertebral fragility fractures.
Gallacher SJ; McQuillian C; Harkness M; Finlay F; Gallagher AP; Dixon T
Curr Med Res Opin; 2005 Sep; 21(9):1355-61. PubMed ID: 16197653
[TBL] [Abstract][Full Text] [Related]
11. [Estimating the economic burden of osteoporotic vertebral fracture among elderly Korean women].
Kang HY; Kang DR; Jang YH; Park SE; Choi WJ; Moon SH; Yang KH
J Prev Med Public Health; 2008 Sep; 41(5):287-94. PubMed ID: 18827495
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis and Treatment of Osteoporosis Before and After Fracture: A Side-by-Side Analysis of Commercially Insured and Medicare Advantage Osteoporosis Patients.
Weaver J; Sajjan S; Lewiecki EM; Harris ST
J Manag Care Spec Pharm; 2017 Jul; 23(7):735-744. PubMed ID: 28650253
[TBL] [Abstract][Full Text] [Related]
13. Incremental cost of medical care after hip fracture and first vertebral fracture: the Rotterdam study.
De Laet CE; van Hout BA; Burger H; Weel AE; Hofman A; Pols HA
Osteoporos Int; 1999; 10(1):66-72. PubMed ID: 10501782
[TBL] [Abstract][Full Text] [Related]
14. Treatment costs and cost drivers among osteoporotic fracture patients in Japan: a retrospective database analysis.
Taguchi Y; Inoue Y; Kido T; Arai N
Arch Osteoporos; 2018 Apr; 13(1):45. PubMed ID: 29696390
[TBL] [Abstract][Full Text] [Related]
15. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
16. Population-Wide Impact of Non-Hip Non-Vertebral Fractures on Mortality.
Tran T; Bliuc D; van Geel T; Adachi JD; Berger C; van den Bergh J; Eisman JA; Geusens P; Goltzman D; Hanley DA; Josse RG; Kaiser SM; Kovacs CS; Langsetmo L; Prior JC; Nguyen TV; Center JR
J Bone Miner Res; 2017 Sep; 32(9):1802-1810. PubMed ID: 28256011
[TBL] [Abstract][Full Text] [Related]
17. Utilization and costs for children who have special health care needs and are enrolled in a hospital-based comprehensive primary care clinic.
Berman S; Rannie M; Moore L; Elias E; Dryer LJ; Jones MD
Pediatrics; 2005 Jun; 115(6):e637-42. PubMed ID: 15930189
[TBL] [Abstract][Full Text] [Related]
18. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group.
Hochberg MC; Ross PD; Black D; Cummings SR; Genant HK; Nevitt MC; Barrett-Connor E; Musliner T; Thompson D
Arthritis Rheum; 1999 Jun; 42(6):1246-54. PubMed ID: 10366118
[TBL] [Abstract][Full Text] [Related]
19. Pharmacoeconomic analysis of osteoporosis treatment with risedronate.
Brecht JG; Kruse HP; Felsenberg D; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2003; 23(4):93-105. PubMed ID: 15224498
[TBL] [Abstract][Full Text] [Related]
20. Cost induced by hip fractures.
Azhar A; Lim C; Kelly E; O'Rourke K; Dudeney S; Hurson B; Quinlan W
Ir Med J; 2008; 101(7):213-5. PubMed ID: 18807812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
